New drug cocktail aims to stop bile duct cancer from coming back
NCT ID NCT07561775
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of two drugs—adebrelimab (given by IV) and S-1 (taken as pills)—can help prevent bile duct cancer from returning after surgery. About 40 adults who had their cancer fully removed will receive the treatment for about 4 months and be monitored for side effects and cancer recurrence. The goal is to see if this approach improves the chance of staying cancer-free one year after surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new test could reveal how radiation affects the liver
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Can matching drugs to tumor genes beat biliary cancer?